Connect with us


Analysis shows 90 per cent of CBD brands third-party test products



Analysis shows 90 per cent of CBD brands third-party test products

A new analysis of CBD product testing has shown that 90 per cent of brands third-party test their products.

With the growing number of CBD products available in stores across Europe and the US, there are concerns among consumers regarding regulatory oversight. A new analysis by industry watchdog, CBD Oracle, has demonstrated that of 520 companies and 20,000 products in Europe and the US 90 per cent of brands carry out third party testing.

The analysis also shows an increase in certified-USDA organic companies, indicating a higher level of self-regulation in an unregulated industry.

Alisdair Mans Cornwell, senior editor at CBD Oracle, commented: ”Despite consumer apprehension being a huge problem, our analysis suggests an industry so conscious of its regulatory shortcomings; it’s taking appropriate steps to fix them.”

“Testing evaluates CBD and THC levels, as well as the presence of pesticides, heavy metals, and solvents. 90% of CBD companies conduct independent, third-party testing on their products and publish all-important Certificates of Analysis as proof. 25 companies are also certified USDA Organic, up by 24 since 2019.

“Third-party testing and USDA certifications aren’t required by law. It’s great to see companies taking the initiative to legitimise the industry, instill confidence in consumers, and ensure product safety and transparency despite the clear lack of federal oversight.”

The analysis highlights, however, that celebrity-owned brands and companies selling CBD drinks are the least transparent, noting that Mike Tyson’s Dwiink brand and Ivan Moody’s Moody’s Medicinals fail to provide extraction method, hemp source, or third-party testing information.

Likewise, the majority of companies specialsing in CBD drinks and beverages don’t disclose their extraction methods or third-party testing.

“The CBD industry certainly isn’t in the clear yet, but this analysis shows it’s doing way better than most expected,” Alisdair concludes.

View full report:


180 Life Sciences collaborates with pioneer to develop CBD analogue

The company has collaborated with the “father of cannabis” Professor Raphi Mechoulam to identify of HUM-217.



180 Life Sciences collaborates with pioneer to develop CBD analogue

Biotechnology company 180 Life Sciences has identified a CBD analogue that will move forward in clinical development for inflammation and pain. 

Born out of a merger of three companies, 180 Life Sciences is focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain. 

A continuing collaboration since 1998 between the “father of cannabis” Professor Raphi Mechoulam, Hebrew University, Jerusalem, co-founder Sir Marc Feldmann’s Laboratory in Oxford, and 180 Life Sciences’ scientists, has led to the identification of a CBD analogue – HUM-217 – which was selected based on a screen of derivatives of CBD and CBG made by Mechoulam and which will be will be advanced to clinical development for chronic pain and early arthritis.

According to the company, the analogue has a novel composition of matter which would enable patent protection, robust preclinical efficacy in several established mouse models for treating pain and inflammation in vivo, and ease of scalability for GMP manufacturing.

Industry veteran and 180 Life Sciences CEO, Dr Jim Woody, commented: “180 Life Sciences is the merger of three companies – one in Israel with Dr Mechoulam, who was working on cannabinoids, one in Oxford, UK, that was working on anti-inflammatory agents, primarily anti-TNF, and one here in the US that works on a nicotinic acid receptor agonist. 

“A long time ago, Dr Feldmann and I were working together and we were the first ones to ever invent an antibody against TNF. We showed it worked in rheumatoid arthritis and Crohn’s disease, psoriasis and ulcerative colitis, and it is now one of the standards of care called Remicade. There are probably 40 million people treated with anti-TNF so there are now no patients with rheumatoid arthritis in wheelchairs because of that drug and the follow on drugs. 

“However, there are problems with anti-TNF’s because the drug is saving the joints but the pain doesn’t totally go away. So, what we are focusing on is making synthetic cannabinoids that will have the ability to be anti-inflammatory and anti-pain. 

“We have now been able to do that – we selected our lead compound to move ahead and go through IND-Enabling studies. We have already tested our compound in inflammation models – there are animal models of inflammation that can give a good readout on whether this works or not – and we know that the compound is effective in those models. With the way it is constructed, it won’t be psychogenic and it is easily absorbed, so we can actually take enough of it or make it into a pill so, people could use it as opposed to regular cannabis that is made up of maybe 100 or more compounds. 

“We will treat patients who have arthritis and receive anti-TNF, but it doesn’t quite make their pain go away, as you do not want your patients to have to use opioids, which is not very satisfactory. Steroids are another problem because of their side effects – a lot of them cause kidney problems, for example. This pill will be non-addictive, and also quite favourable for the pain. 

“It turns out that there are two TNF-receptors, and one of them is inflammatory and the other one is anti-inflammatory so, down the road, we are going to make specific drugs against each of those to try to get away from the infectious disease complications. So, it is a whole new novel area but Dr Feldmann and I and others are very familiar with the TNF field.”

Dr Woody says that the anlaogue would be added to the regimen of doctors prescribing anti-TNFs as a large clinical trial, possibly all over Europe. Additionally, he says 180 Life Sciences are licensing more compounds from Oxford that have unique abilities to help tissue regrow after is damaged.

“In the cannabinoid area, I think this class of drugs probably has a lot of uses. Certainly, it’s being used in paediatric seizures and things like post-traumatic stress disorder, but these are not clean compounds, they are very complicated. 

“So, I think for the field to move ahead, we need to do what we are doing – making very specific medicines and molecules, so we know what they are, we know how they work, and then we can address many of these other problems because there is a whole range of therapeutics there that will be quite helpful that I think will be tailored for different diseases.”

The company recently raised $15m through private placement, which will fund general corporate purposes, working capital, and the research and development of its programmes which are not funded by grants.

“We raised the funds to accelerate these programmes moving forward. It will almost all go into the projects themselves. We don’t have an office because we’re scattered between Israel and Oxford and Palo Alto and so, we plan to put almost all the money into the programmes and get them to move more quickly.”

Continue Reading


World’s first medical-grade vapouriser now available in the UK

Kanabo’s VapePod can now be purchased on Handpicked CBD.



World’s first medical-grade vapouriser now available in the UK

The world’s first medical-grade vapouriser – the VapePod – is now available to UK customers. 

Customers in the UK can now purchase Kanabo’s VapePod on Handpicked CBD, which enables tracking of exactly how much CBD is best using metered dosing.

UK-based Kanabo, which has carried out extensive R&D in order to develop innovative medical-grade vapourisers and various non-smoking consumption solutions, has enabled the vape to be used with its three new proprietary formulas: Reload, Relax and Repair.

The high-quality pure hemp distillate CBD formulas contain up to 86% cannabinoids and the vapourisation of CBD means it is fast-acting compared to other products like tinctures or edibles. Each cartridge that goes into the VapePod contains 360mg of CBD and has a blend of terpenes, give more than 300 doses lasting between six to eight weeks.

Kanabo CEO, Avihu Tamir commented: “We are delighted to offer our CBD wellness line through Handpicked CBD. 

“Consumers now have access to the strongest yet non-intoxicating CBD formulas with only the highest quality of ingredients. Kanabo’s R&D team has created these fast-acting formulas with the health and wellness of consumers in mind.”

HandPickedCBD, a Materia asset, currently features more than 50 brands and more than 500 different products, all of which must satisfy a list of quality and safety criteria before they are featured on the platform. It is The Marketplace for the best of all CBD products available online in the UK. 

The platform highlights the benefit of the proposed partnership between Kanabo and Materia that will make Kanabo the largest medicinal cannabis company in Europe.

Kanabo intends to add more to its portfolio of products as the brand grows.

Continue Reading


British cannabis pioneer expands global reach with launch in Asia

Always Pure Organics (APO), has officially launched its new Asia foothold, Always Pure Organics Japan.



Always pure organics

Pioneering and market-leading cannabis specialist, Always Pure Organics (APO), has officially launched its new Asia foothold – Always Pure Organics Japan.

The move takes the Manchester-headquartered company’s already strong trading position in the fast-growing Japanese market to make it one of the first European brands to be established on the island. 

Exporting success 

APO is a top three wholesale and white label market leader in the UK, Japan and Europe, and registering its own company in Japan creates a strong base in a country where the CBD market is beginning to boom.  

With more than 80 percent of APO’s business primarily focused on export and following the recent acquisition of Belgian company DLH*, giving it a strong European footprint, APO intends to repeat this ambitious strategy by creating a base in Japan to allow it to grow within the wider Asia region.

By establishing APO Japan, the company, as well as increasing its wholesale and white label business, it now creates the opportunity to distribute its own brands across this key market. 

APO began trading in Japan in 2019, and since then has built a reputation for quality and reliability in the rapidly growing Japanese CBD market, where an in-depth of knowledge and experience of the country’s strict import regulations is essential. In the two years since the company began trading in Japan, it has achieved revenue of more than £2.5m and by establishing this base expects sales to rise to £4.5m in the first 12 months alone. 

First mover advantage

APO is already recognised as one of the most trusted manufacturing partners in the Japanese market. Establishing APO Japan allows the company to manufacture on the island, to import raw material quicker, register products faster and thereby gives the company a competitive advantage by being locally based. 

Given that it can take several months for Western brands to get their product into the market, by having its own domestic manufacturing and distribution warehouse facilities this will allow APO to capitalise on this key FMCG market as well using its new foothold to expand further into Asia.  

CEO Gavin Ogilvie, commented: “When operating in the EU, APO is afforded the freedom to distribute its goods duty and tax free throughout the EU on a next day basis.  However, in Japan, the customs clearance process slows this down dramatically and results in lengthy lead times. By establishing ourselves in Japan and building on our experience from the previous two years, our clients are able to benefit from our new, faster, local based service.”

Corporate social responsibility

Since June 2020 APO has been engaged with Green Zone Japan in joint preclinical studies called ‘Midori-no-wa (Green Circle)’ for children with intractable epilepsy in Japan. Green Zone Japan is a Japanese medical cannabis advocacy group focusing on bringing evidence-based, accurate and up-to-date information on medical cannabis to Japanese medical professionals and the public. 

By now being based in Japan, APO is in a stronger position to further support Green Zone Japan and other organisations researching the benefits of CBD and other cannabinoids.  

Regional director for Asia and the country representative of Japan, Chikako Yoshida said: “Evolution in the cannabis industry is fast moving particularly with inspiring stories embracing users and patients who are experiencing great benefits from the plant. After observing the evolution of the CBD industry in Japan – a country with an extremely positive outlook for the year ahead, we have therefore decided that now was the right time to launch APO Japan to respond quicker and more efficiently to the industry demands.”

This content was created in collaboration with our industry partners, whose support ensures we can continue serving our readership.

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts